Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of “Buy” from Analysts

Trevi Therapeutics, Inc. (NASDAQ:TRVI) has been assigned a consensus recommendation of “Buy” from the twelve ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, nine have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $22.90.

Several research firms have weighed in on TRVI. Stifel Nicolaus set a $30.00 price objective on shares of Trevi Therapeutics in a research note on Friday, May 8th. D. Boral Capital restated a “buy” rating and set a $19.00 price target on shares of Trevi Therapeutics in a research note on Friday, April 17th. JonesTrading dropped their price target on shares of Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research note on Thursday, March 19th. HC Wainwright restated a “buy” rating and set a $21.00 price target on shares of Trevi Therapeutics in a research note on Wednesday, May 6th. Finally, Needham & Company LLC restated a “buy” rating and set a $23.00 price target on shares of Trevi Therapeutics in a research note on Wednesday, May 20th.

Institutional Trading of Trevi Therapeutics

Hedge funds have recently bought and sold shares of the stock. Russell Investments Group Ltd. boosted its holdings in Trevi Therapeutics by 194.5% in the 2nd quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock valued at $25,000 after purchasing an additional 2,996 shares during the period. KBC Group NV bought a new stake in Trevi Therapeutics in the 1st quarter valued at $29,000. Hilton Head Capital Partners LLC bought a new stake in Trevi Therapeutics in the 4th quarter valued at $40,000. Caitong International Asset Management Co. Ltd bought a new stake in Trevi Therapeutics in the 4th quarter valued at $50,000. Finally, Strs Ohio bought a new stake in Trevi Therapeutics in the 1st quarter valued at $52,000. 95.76% of the stock is owned by institutional investors.

Trevi Therapeutics Stock Performance

Trevi Therapeutics stock opened at $16.37 on Thursday. The firm has a market cap of $2.32 billion, a PE ratio of -51.16 and a beta of 1.04. The firm’s 50 day moving average price is $14.16 and its two-hundred day moving average price is $12.56. Trevi Therapeutics has a twelve month low of $5.41 and a twelve month high of $16.80.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.02). Equities analysts anticipate that Trevi Therapeutics will post -0.47 EPS for the current fiscal year.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.